quarterly return from 2018 vktx

Viking Therapeutics (VKTX) had its best quarter since 2018 in Q1 2024, returning 342.5%.

ASSET	QUARTER	% RETURN
Viking Therapeutics (VKTX)	Q1 2018	6.85%
Viking Therapeutics (VKTX)	Q2 2018	119.17%
Viking Therapeutics (VKTX)	Q3 2018	83.18%
Viking Therapeutics (VKTX)	Q4 2018	-57.97%
Viking Therapeutics (VKTX)	Q1 2019	34.32%
Viking Therapeutics (VKTX)	Q2 2019	-18.23%
Viking Therapeutics (VKTX)	Q3 2019	-18.1%
Viking Therapeutics (VKTX)	Q4 2019	16.57%
Viking Therapeutics (VKTX)	Q1 2020	-43.27%
Viking Therapeutics (VKTX)	Q2 2020	65.75%
Viking Therapeutics (VKTX)	Q3 2020	-18.72%
Viking Therapeutics (VKTX)	Q4 2020	-3.26%
Viking Therapeutics (VKTX)	Q1 2021	10.96%
Viking Therapeutics (VKTX)	Q2 2021	-5.67%
Viking Therapeutics (VKTX)	Q3 2021	3.8%
Viking Therapeutics (VKTX)	Q4 2021	-26.52%
Viking Therapeutics (VKTX)	Q1 2022	-35.76%
Viking Therapeutics (VKTX)	Q2 2022	-3.99%
Viking Therapeutics (VKTX)	Q3 2022	-5.56%
Viking Therapeutics (VKTX)	Q4 2022	240.58%
Viking Therapeutics (VKTX)	Q1 2023	81.18%
Viking Therapeutics (VKTX)	Q2 2023	-3.66%
Viking Therapeutics (VKTX)	Q3 2023	-31.11%
Viking Therapeutics (VKTX)	Q4 2023	69.18%
Viking Therapeutics (VKTX)	Q1 2024	342.53%

Related Searches